Oncologist Mikhail Blagosklonny has committed his time, talent and ideas to research and sharing information to help find new ways to prevent, treat and cure cancer and illnesses that beset the aged. He passes on the information on medical breakthroughs and other examples of effective treatments through his work as an oncology professor with Roswell Park Cancer Institute. He also disseminates information from scholarly papers written by some of the world’s top physicians and researchers in Oncotarget, a weekly open source peer-reviewed journal he edits.
Mikhail Blagosklonny is a graduate of First Pavlov State Medical University in St. Petersburg. While there he earned an M.D. in internal medicine. He also completed a PhD in cardiology and experimental medicine on Nature.com. Shortly after graduation New York Medical College in Valhalla hired Blagosklonny as an associate professor of medicine. Next he became an Ordway Research Institute senior scientist. Blagosklonny excelled in the position and kept the job until 2009. At that point he began to work at Roswell Park Cancer Institute as an oncology professor.
The areas into which Blogosklonny does research include cancer and aging related illnesses and conditions. His work also focuses on targeted cancer therapies which prevent normal cells from being damaged during treatment, the mechanisms underlying aging as well as anti-aging drugs on tandfonline.com. He is known as a passionate advocate of the use of the cancer drug rapamycin in longevity research. Blagosklonny is also credited with a hypothesis related the possible role TOR signaling may play in aging and cancer and using rapamycin to help extend life for the elderly.
Blagosklonny is also involved in a wide range of editorial activities at http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=3740. He’s Oncotarget, Cell Cycle and Aging’s editor-in-chief. He’s also an associate editor with Cancer Biology & Therapy. In addition, Blagosklonny is a Cell Death & Differentiation editorial board member. He has published 275 research items and his work has been cited over 21,300 times. One of his articles was entitled:’Dual MTORC1/C2 inhibitors suppress cellular geroconversion’. Another was ‘Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats’. ‘Rejuvenating immunity: “anti-aging drug today” eight years later’ is another of Blagosklonny popular articles.
At Roswell Park Cancer Institute in Buffalo, New York Blagosklonny works in the Department of Cell Stress Biology and is deeply involved in work related to Hematology, clinical trials and Oncology. He’s also an expert on signal transduction, phosphorylation, protein kinases and several other areas.